Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Mepolizumab Market Forecast Highlighting Growth From $2.38 Billion To $3.21 Billion
The mepolizumab market has experienced strong growth in recent years. It is forecast to grow from $2.22 billion in 2025 to $2.38 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. The expansion witnessed in the past can be attributed to the increasing prevalence of severe asthma, a greater understanding of eosinophilic disorders, advancements in biologics research and development, the broadening of specialty care services, and improved diagnostic capabilities for inflammatory diseases.
The mepolizumab market is anticipated to show robust expansion over the next few years, projected to reach $3.21 billion by 2030, with a compound annual growth rate (CAGR) of 7.7%. This growth during the forecast period can be linked to an intensified focus on personalized medicine, the broadening pipeline of biologics, an increasing demand for at-home treatment options, advancements in targeted immunotherapies, and rising healthcare investments in the management of chronic diseases. Prominent trends expected in the forecast period involve the increasing adoption of monoclonal antibody therapies, the growing utilization of biologics for severe asthma management, a heightened demand for steroid-sparing treatment options, expanding clinical applications for eosinophilic disorders, and improved patient adherence achieved through targeted therapies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample_request?id=29065622&type=smp
Mepolizumab Market Growth Momentum: Which Factors Are Influencing Demand?
The expanding worldwide prevalence of asthma is projected to drive the expansion of the mepolizumab market in the future. Asthma is defined as a long-term respiratory ailment characterized by inflammation and narrowing of the airways (bronchi), leading to excessive mucus production and breathing difficulties. The increased occurrence of asthma results from individuals encountering both genetic and environmental elements, which can provoke airway inflammation and heighten lung sensitivity, thereby escalating asthma’s prevalence. Mepolizumab addresses asthma by facilitating the decrease in inflammation initiated by eosinophils, a specific kind of white blood cell involved in airway swelling and asthma exacerbations. For example, data from February 2026, provided by the Australian Institute of Health and Welfare (AIHW), an independent statutory agency based in Australia, indicates that asthma accounts for 2. 5% of Australia’s overall disease burden in 2024, stands as the primary cause of disease burden among children aged 1-9, generates approximately $1. 3 billion in healthcare expenditure during 2023-24, and presents greater prevalence and hospitalization rates in boys compared to girls. Additionally, as reported in February 2023 by NHS England, a UK-based executive non-departmental public body, roughly 5. 4 million people are receiving treatment for asthma, with about 160,000 new cases identified each year, and occupational factors playing a role in nearly 9–15% of asthma cases that develop in adulthood. Consequently, the expanding worldwide impact of asthma is fueling the market growth for mepolizumab.
Mepolizumab Market Segmentation: How Is The Market Structured Across Key Categories?
The mepolizumab market covered in this report is segmented –
1) By Indication: Severe Asthma, Eosinophilic Granulomatosis With Polyangiitis, Chronic Obstructive Pulmonary Disease, Other Eosinophilic Disorders
2) By Age Group: Children 6 To 11 Years, Adolescents 12 To 17 Years, Adults 18 Years And Older
3) By Distribution Channel: Direct Sales, Retail Pharmacy, Online Pharmacy
4) By End User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Severe Asthma: Allergic Severe Asthma, Non Allergic Severe Asthma, Late Onset Severe Asthma
2) By Eosinophilic Granulomatosis With Polyangiitis: Active Eosinophilic Granulomatosis With Polyangiitis, Relapsing Eosinophilic Granulomatosis With Polyangiitis, Remission Phase Eosinophilic Granulomatosis With Polyangiitis
3) By Chronic Obstructive Pulmonary Disease: Chronic Bronchitis Dominant Chronic Obstructive Pulmonary Disease, Emphysema Dominant Chronic Obstructive Pulmonary Disease, Frequent Exacerbator Chronic Obstructive Pulmonary Disease
4) By Other Eosinophilic Disorders: Hypereosinophilic Syndrome, Eosinophilic Esophagitis, Eosinophilic Chronic Rhinosinusitis
Mepolizumab Market Trends Reshaping Industry Growth
Leading companies within the mepolizumab market are prioritizing the creation of novel offerings, specifically eosinophil-targeting biologics, with the aim of broadening therapeutic applications and enhancing patient care results. These biologics are a type of monoclonal antibody treatment designed to suppress interleukin-5, thereby mitigating inflammation caused by eosinophils. An example of this trend occurred in January 2026, when GlaxoSmithKline PLC, a UK-based biopharmaceutical company, publicized the endorsement of Nucala (mepolizumab) by China’s National Medical Products Administration (NMPA). This particular treatment shows notable decreases in moderate to severe flare-ups for individuals suffering from eosinophilic chronic obstructive pulmonary disease, especially when combined with conventional inhaled medications. The authorization of this treatment introduces a specific biologic alternative for a significant number of patients, contributing to better clinical results and alleviating the strain of hospitalizations.
Mepolizumab Market Competitive Landscape And Leading Companies
Major companies operating in the mepolizumab market are GlaxoSmithKline plc, Bio‑Thera Solutions Ltd.
Access The Complete Mepolizumab Market Report:
https://www.thebusinessresearchcompany.com/report/mepolizumab-market-report
Mepolizumab Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the mepolizumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mepolizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.